Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New targets for Ph+ leukaemia therapy.

Best practice & research. Clinical haematology - 1 Sept 2009

Martinelli Giovanni, Iacobucci Ilaria, Papayannidis Cristina, Soverini Simona

Abstract excerpt

The outcome for adults with Philadelphia chromosome (Ph+) leukaemias (chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL)) has been dramatically improved with the use of tyrosine kinase inhibitors (TKIs), but progression and/or relapse are still present in the majority of pati...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PAX5 gene
Share to Drug Delivery Systems
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BCR gene

Share to Gene Expression Profiling

Share to Gene Expression Regulation, Neoplastic

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 19959093
DOI: 10.1016/j.beha.2009.08.002

Genes

BCR
PAX5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19959093-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New targets for Ph+ leukaemia therapy.PMID 19959093Read ↗

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome‐positive adult acute lymphoblastic leukemiaSemantic proximity Read ↗

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia.Semantic proximity Read ↗

How has the management of Ph+ acute lymphoblastic leukemia (ALL) changed over the years.Semantic proximity Read ↗

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in AdultsSemantic proximity Read ↗

Management of adult Ph-positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia: A New Era of ChallengesSemantic proximity Read ↗

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.Semantic proximity Read ↗

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challengesSemantic proximity Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic AnemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.